Loading organizations...
§ Venture Capital · San Francisco, CA, USA
Venture capital firm investing in early to commercial-stage medtech companies, focused on cardiovascular and neurovascular innovations.
415 Capital is a venture capital firm based in Munich, Germany, that invests in early to commercial-stage medical technology companies developing treatments for cardiovascular and neurovascular diseases. The firm focuses on startups addressing chronic conditions such as heart failure, stroke, and hypertension across Europe, Israel, and the United States. Operating with over 12 employees, the firm writes initial checks ranging from €5 million to €15 million for Series A, Series B, and growth equity rounds. The firm targeted €85 million for its first fund in 2020 and announced a €150 million target for its second fund in October 2024. 415 Capital is backed by institutional investors like the European Investment Fund and KfW Capital, maintaining a portfolio that includes Supira Medical, R3 Vascular, and Distalmotion. The firm was founded in 2018 by Frank Groenewegen, Frederik Groenewegen, and David Thompson.
Key people at 415 CAPITAL.
415 CAPITAL was founded in 2018 by Owen van Natta (Founder and Managing Partner).
Key people at 415 CAPITAL.
415 CAPITAL has 8 tracked investments across 7 companies. The latest tracked deal is $48.0M Series B in CorFlow Therapeutics in September 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2024 | CorFlow Therapeutics | $48.0M Series B | Broadview Ventures, Panakes Partners | — |
| May 20, 2024 | R3 Vascular | $87.0M Series B | Mike Hurley, MD, MS | 415 Capital |
| Mar 4, 2024 | Hilo | $30.6M Other Equity | Redalpine | 415 Capital, Draper Esprit, Khosla Ventures, Translink Capital, Verve Ventures |
| Jan 26, 2022 | Distalmotion | $90.0M Series E | Rick Anderson | 415 Capital |
| Nov 8, 2021 | Aktiia | $17.5M Series A | Inga Deakin | 415 Capital, Redalpine, Translink Capital, Verve Ventures |
| Jun 24, 2021 | Cardiac Success | $5.2M Series A | 415 Capital | — |
| Apr 1, 2021 | Moray Medical | $6.0M Seed | 415 Capital | Fred ST. Goar, MD, Christian Weiss |
| Oct 8, 2020 | R3 Vascular | $17.8M Other Equity / Series A | 415 Capital | HBM Medfocus, Wexford Capital |
415 CAPITAL was founded in 2018 by Owen van Natta (Founder and Managing Partner).
415 Capital is a Munich-based specialist venture capital firm focused exclusively on breakthrough medical technology (MedTech) innovation. The firm’s mission is to advance life-saving healthcare solutions by investing in early- and clinical-stage companies that are pioneering novel therapies and devices, particularly in cardiovascular and neurovascular disease. 415 Capital’s investment philosophy centers on backing entrepreneurs with transformative technologies, providing not only capital but also strategic guidance and access to a global network of clinical and industry experts. Its portfolio spans Europe, the United States, and Israel, with a strong emphasis on technologies that address unmet clinical needs and improve patient outcomes. Over the past decade, the firm has played a pivotal role in the MedTech startup ecosystem, supporting more than 50 companies and facilitating multiple high-profile exits to major medical device corporations.
Founded in 2018, 415 Capital was established by a team of seasoned healthcare investors led by Frank Groenewegen, David Thompson, and Frederik Groenewegen. The firm’s roots trace back to decades of experience in MedTech investing, with its partners having previously funded and guided numerous successful startups in the sector. The launch of 415 Capital marked a strategic shift toward a more focused, institutional approach to venture capital, with the goal of scaling impact by concentrating on clinical-stage innovations. The firm’s first institutional fund closed in 2020, followed by a second, larger fund in 2025, reflecting strong investor confidence and a growing pipeline of high-potential MedTech opportunities. Over time, 415 Capital has evolved from a regional player to a globally recognized force in MedTech venture capital.
415 Capital is riding the wave of rapid innovation in medical technology, where advances in robotics, artificial intelligence, and minimally invasive therapies are transforming patient care. The timing is particularly favorable as healthcare systems worldwide seek more effective, cost-efficient solutions for chronic diseases like cardiovascular disorders. The firm’s focus on clinical-stage companies positions it at the intersection of scientific discovery and commercialization, helping to bridge the gap between research and real-world impact. By supporting startups that are developing next-generation devices, 415 Capital is not only shaping the future of MedTech but also influencing broader trends in healthcare delivery, patient monitoring, and digital health integration.
Looking ahead, 415 Capital is poised to deepen its impact as MedTech innovation accelerates and demand for life-saving technologies grows. The firm’s recent expansion with a €150 million second fund signals its ambition to back even more high-potential startups and drive further breakthroughs in cardiovascular and neurovascular care. As the boundaries between medicine, technology, and data continue to blur, 415 Capital’s specialized expertise and global network will be increasingly valuable. The firm’s influence is likely to grow, not just in terms of financial returns but also in its ability to shape the future of healthcare by empowering the next generation of MedTech pioneers.